Trevena up 390% on Chinese drug approval - too much or not enough?

Trevena (NASDAQ: TRVN) stock has a number of suspicious little hallmarks. It's also possible that there's something real here. So, we should pay attention to the details to see whether this is some passing meme stock item or whether there's something real that has actually happened here. The answer, to avoid narrative uncertainty, is that there's something real here although whether it's worth quite this much is another matter. 

The red signals here are that Trevena is a small cap - $6 million market cap perhaps - and the news is about China. Well, we've seen China focused microcaps become playthings of the stonks to the Moon crowd quite enough recently to at least have our suspicions here. So we could think that a 390% rise in one day (with another 10% post market on top) is just another cycle of the meme stock games. 

On the other hand Trevena is a pharma development company and they're one of the few that could, legitimately, receive the sort of news that leads to jumps like this. The approval of a drug candidate for example - that could be worth 300 and 400% on a stock price. Maybe, obviously, but it is feasible.

Trevena stock price from NASDAQ

Which is what has happened here at Trevena. An opioid they have under development has received approval for marketing in China. This then triggers payments from their partner in that market, Jiangsu Nwha. That triggers a $3 million payment from Jiangsu to Trevena, which is good and nice. Upon an actual first commercial sale in China there's another $15 million payment triggered from a royalty sales agreement the company has. That's even better. 

So, pharma development company has developed something that works, will sell. Good, that's a valuation event if ever there were one. Given that starting point of a $6 million market cap 400% and change doesn't seem an outrageous price change on news to get up to $18 million in near immediate revenue. 

However, there's one more thing to think about here. Speaking roughly, very roughly you understand. Trevena loses - of course, it's a development company, it loses money - $50 million a year. It has some $50 million (again, we're using rough numbers here) in cash and cash equivalents. That's a 12 month runway. We'd not think that this one opioid, in one market, is going to cover that within the next 12 months. The up to $18 million to be received under this deal doesn't, therefore, solve the corporate financing problem. 

This recent jump in the stock price does though. There're some 5 million new shares that can be issued under old authorisations. We would expect an issuance of stock to the market in order to cover that financing need. Not perhaps today or tomorrow but we'd expect it shortly enough, using this strength in the stock price to raise money with as little dilution as possible.